Sugi Predict

Sugi Predict / Compounds / SCHEMBL3022499

SCHEMBL3022499

SCHEMBL3022499

O=c1[nH][nH]c(=O)n1-c1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GSK3A P49840 2/20 0.60
▸ GSK3B P49841 2/20 0.60
▸ GAA P10253 2/20 0.60
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ POLB P06746 1/20 0.50
▸ MGLL Q99685 1/20 0.46
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ ALOX5 P09917 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ HPGD P15428 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ ELANE P08246 1/20 0.42
▸ TSHR P16473 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ APOBEC3G Q9HC16 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31090336 0.86 MAPT (0.50) GSK3AGSK3BGAASMN1; SMN2POLB
SCHEMBL6219762 0.78 GAA (0.50) GSK3AGSK3BGAASMN1; SMN2POLB
SCHEMBL9623389 0.77 POLB (0.56) GSK3AGSK3BSMN1; SMN2POLBMGLL
SCHEMBL11876869 0.76 GAA (0.60) GSK3AGSK3BGAASMN1; SMN2POLB
SCHEMBL3021600 0.76 GSK3A (0.60) GSK3AGSK3BGAASMN1; SMN2POLB
SCHEMBL5328006 0.76 GSK3A (0.60) GSK3AGSK3BGAASMN1; SMN2MGLL
SCHEMBL6806339 0.76 GAA (0.48) GSK3AGSK3BGAASMN1; SMN2POLB
SCHEMBL11882558 0.76 GAA (0.60) GSK3AGSK3BGAASMN1; SMN2POLB
SCHEMBL11363821 0.76 GSK3A (0.60) GSK3AGSK3BGAASMN1; SMN2POLB
SCHEMBL11608487 0.76 TP53 (0.53) GSK3AGSK3BGAAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0401895-B1 AQUEOUS FOLINATE SOLUTION STABLE AT REFRIGERATOR TEMPERATURE, AS WELL AS PROCESS FOR ITS PREPARATION PHARMACHEMIE B.V. (NL) 1992-12-23 — — EP claimed
EP-0401895-A1 Aqueous folinate solution stable at refrigerator temperature, as well as process for its preparation PHARMACHEMIE B.V. (NL) 1990-12-12 — — EP claimed
WO-1990000897-A1 METHOD FOR THE CONTROL OF HYPERLIPIDEMIA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1990-02-08 — — WO claimed
US-4866058-A TRIAZOLIDINE-BIONES, TRIAZABICYCLOHEXANEDIONES, AND TRIAZINE-DIONES NORTH CAROLINA AT CHAPEL HILL, THE UNIVERSITY OF 1989-09-12 — — US claimed
CN-113445355-B Composition, method for producing same, toilet paper with same, and processing method using same 中顺洁柔纸业股份有限公司 2024-03-26 — — CN disclosed
CN-117004324-A Polishing solution and polishing method for laser gyro cavity 湖南二零八先进科技有限公司 2023-11-07 — — CN disclosed
CN-219314757-U Inorganic and analytical chemistry laboratory waste liquid collecting and treating device 合肥工业大学 2023-07-07 — — CN disclosed
US-20100190795-A1 BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) 2010-07-29 — — US disclosed
US-5192761-A 1,2,4-triazolidine-3,5-diones and 1,3,5-triazine-2,4(1-H,3H)-diones, pharmaceutical compositions NORTH CAROLINA CENTRAL UNIV. (US) 1993-03-09 — — US disclosed
US-5177076-A Complexing Agents for Calcium PHARMACHEMIE BV (NL) 1993-01-05 — — US disclosed
EP-0401895-B1 AQUEOUS FOLINATE SOLUTION STABLE AT REFRIGERATOR TEMPERATURE, AS WELL AS PROCESS FOR ITS PREPARATION PHARMACHEMIE B.V. (NL) 1992-12-23 — — EP disclosed
US-5034528-A 1,3,5-triazabicyclo 3.1.0!hexane-3,5-diones NORTH CAROLINA CENTRAL UNIVERSITY (US) 1991-07-23 — — US disclosed
US-4866058-A TRIAZOLIDINE-BIONES, TRIAZABICYCLOHEXANEDIONES, AND TRIAZINE-DIONES NORTH CAROLINA AT CHAPEL HILL, THE UNIVERSITY OF 1989-09-12 — — US disclosed
EP-0045371-B1 PREPARATION OF 4-SUBSTITUTED 1,2,4-TRIAZOLIDINE-3,5-DIONES BAYER AG (DE) 1984-02-22 — — EP disclosed
US-4429135-A REACTION WITH PRIMARY AMINE BAYER AKTIENGESELLSCHAFT (DE) 1984-01-31 — — US disclosed
EP-0045371-A2 Preparation of 4-substituted 1,2,4-triazolidine-3,5-diones BAYER AG (DE) 1982-02-10 — — EP disclosed
EP-0033503-A2 Medicaments with cytostatic activity and use of cyclic compounds, in which the heterocyclic N-ring atoms are substituted by several glycidyl groups, in pharmaceutical compositions Henkel Kommanditgesellschaft auf Aktien (DE) 1981-08-12 — — EP disclosed
US-4249934-A 1,2-Alkylene-4-substituted urazole herbicides MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) 1981-02-10 — — US disclosed
US-4087534-A N-haloalkylmio urazole pesticides OVADIA DAVID 1978-05-02 — — US disclosed
US-4066437-A TRIAZOLIDINE COMPOUNDS USEFUL AS HERBICIDES CIBA-GEIGY CORPORATION (US) 1978-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190795-A1 BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS BET1, BECN1, PGGT1B GSK3A 652/4885GSK3B 829/4885GAA 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.